T-MAXIMUM is a clinical-stage cell therapy company dedicated to developing allogeneic CAR-T products for solid tumors amenable to locoregional delivery. Our lead programs focus on high-unmet-need intracranial tumors, including recurrent glioblastoma and brain metastases.
| Program | Target / Focus | Research | Preclinical | Clinical exploration | Global clinical development |
| MT027 | B7-H3 Recurrent glioblastoma | ||||
| MT027 | B7-H3 Brain metastases | ||||
| MT029 | EGFR Solid tumor | ||||
| MT026/MT028 | IL-13Rα2 / HER2 Solid tumors |
| Supporting development | MT027-CDx | B7-H3 IHC companion diagnostic: supporting patient selection and subsequent clinical development |
BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent g…
In 2025, with the strong support of governments at all levels, investment institutions and industrial partners, T-MAXIMUM Biotech will continue to promote technological innovation and industrialization process, taking breakthrough universal CAR-T technology as the foundation.
[Yokohama, Japan - August 8, 2024] - At the highly anticipated 2024 ASCO Breakthrough Summit, T-MAXlMUNM Biotech, which focuses on the development of universal cell drugs, It has been highly praised by the international medical community for its pioneering achievements in the field of allo…
On November 4th, the first event of the "Suzhou Biomedical Collaborative Innovation Enhancement Action Plan" - a symposium in the field of cell therapy - was successfully held.